Pitzer, Virginia E. https://orcid.org/0000-0003-1015-2289
Ndeketa, Latif
Asare, Ernest O. https://orcid.org/0000-0003-4078-8755
Hungerford, Daniel
Lopman, Benjamin A.
Jere, Khuzwayo C.
Cunliffe, Nigel A.
Funding for this research was provided by:
DH | National Institute for Health Research (NIHR133066, NIHR133066, NIHR133066, PDF-2018-11-ST2-006, NIHR133066, NIHR133066, NIHR203756)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI112970, R01AI112970, R01AI112970, R01AI112970)
Wellcome Trust (091909/Z/10/Z, 091909/Z/10/Z)
Bill and Melinda Gates Foundation (OPP1180423 and INV-046917, OPP1180423 and INV-046917)
U.S. Department of Health & Human Services | Centers for Disease Control and Prevention (2018/815189-0 through WHO, 2018/815189-0 through WHO)
Article History
Received: 17 June 2024
Accepted: 23 October 2024
First Online: 19 November 2024
Competing interests
: D.H. is currently receiving grant support from Seqirus UK Ltd for the evaluation of influenza vaccines and grant support and personal consultancy fees from Merck & Co (Kenilworth, New Jersey, USA) for rotavirus strain surveillance; D.H. received honoraria for a presentation at a Merck Sharp & Dohme (UK) Limited symposium on vaccines; and D.H. has previously received research-initiated and industry-initiated research grant support from GlaxoSmithKline Biologicals for evaluation of rotavirus vaccination in the UK and from GSK, Sanofi Pasteur, and Merck & Co for rotavirus strain surveillance. BAL reports personal fees from Epidemiological Research and Methods, LLC. MO and reports receiving grants and research support from Janssen Vaccines & Prevention B.V., Bharat Biotech International Limited, and HilleVax Inc. outside of the submitted work. K.C.J. has received research grant support from GlaxoSmithKline Biologicals for work on rotavirus vaccines. All other authors declare no competing interests.